Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

T. K. Owonikoko; K. P. Papadopoulos; M. Gil-Martin; V. Moreno; A. K. Salama; E. Calvo; H. Safran; A. González-Martín; R. Aljumaily; D. Mahadevan; J. Niu; K. Kal Mohan; J. Li; E. Stankevich; M. Mathias; I. Lowy; M. G. Fury; H. M. Babiker

doi:10.1093/annonc/mdy289.048

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

T. K. Owonikoko
, K. P. Papadopoulos
, M. Gil-Martin
, V. Moreno
, A. K. Salama
, E. Calvo
, H. Safran
, A. González-Martín
, R. Aljumaily
, D. Mahadevan
, J. Niu
, K. Kal Mohan
, J. Li
, E. Stankevich
, M. Mathias
, I. Lowy
, M. G. Fury
, H. M. Babiker

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii461-viii462
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy289.048
State	Published - Oct 1 2018
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy289.048

Cite this

Owonikoko, T. K., Papadopoulos, K. P., Gil-Martin, M., Moreno, V., Salama, A. K., Calvo, E., Safran, H., González-Martín, A., Aljumaily, R., Mahadevan, D., Niu, J., Kal Mohan, K., Li, J., Stankevich, E., Mathias, M., Lowy, I., Fury, M. G., & Babiker, H. M. (2018). Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii461-viii462. https://doi.org/10.1093/annonc/mdy289.048

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. / Owonikoko, T. K.; Papadopoulos, K. P.; Gil-Martin, M. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii461-viii462.

Research output: Contribution to journal › Article › peer-review

Owonikoko, TK, Papadopoulos, KP, Gil-Martin, M, Moreno, V, Salama, AK, Calvo, E, Safran, H, González-Martín, A, Aljumaily, R, Mahadevan, D, Niu, J, Kal Mohan, K, Li, J, Stankevich, E, Mathias, M, Lowy, I, Fury, MG & Babiker, HM 2018, 'Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii461-viii462. https://doi.org/10.1093/annonc/mdy289.048

Owonikoko TK, Papadopoulos KP, Gil-Martin M, Moreno V, Salama AK, Calvo E et al. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii461-viii462. doi: 10.1093/annonc/mdy289.048

Owonikoko, T. K. ; Papadopoulos, K. P. ; Gil-Martin, M. et al. / Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) : Longer follow-up efficacy and safety data. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii461-viii462.

@article{e3e0764b4f5647539b56361651d532f9,

title = "Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data",

author = "Owonikoko, \{T. K.\} and Papadopoulos, \{K. P.\} and M. Gil-Martin and V. Moreno and Salama, \{A. K.\} and E. Calvo and H. Safran and A. Gonz{\'a}lez-Mart{\'i}n and R. Aljumaily and D. Mahadevan and J. Niu and \{Kal Mohan\}, K. and J. Li and E. Stankevich and M. Mathias and I. Lowy and Fury, \{M. G.\} and Babiker, \{H. M.\}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy289.048",

language = "English (US)",

volume = "29",

pages = "viii461--viii462",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)

T2 - Longer follow-up efficacy and safety data

AU - Owonikoko, T. K.

AU - Papadopoulos, K. P.

AU - Gil-Martin, M.

AU - Moreno, V.

AU - Salama, A. K.

AU - Calvo, E.

AU - Safran, H.

AU - González-Martín, A.

AU - Aljumaily, R.

AU - Mahadevan, D.

AU - Niu, J.

AU - Kal Mohan, K.

AU - Li, J.

AU - Stankevich, E.

AU - Mathias, M.

AU - Lowy, I.

AU - Fury, M. G.

AU - Babiker, H. M.

PY - 2018/10/1

Y1 - 2018/10/1

UR - https://www.scopus.com/pages/publications/85081530983

UR - http://www.scopus.com/inward/citedby.url?scp=85081530983&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy289.048

DO - 10.1093/annonc/mdy289.048

M3 - Article

C2 - 32137181

SN - 0923-7534

VL - 29

SP - viii461-viii462

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this